Multiomics Tumor Evolution Model of NSCLC
Recruiting · NCT05352035 · Observational (researchers observe without assigning treatment) · Lead sponsor: Peking University People's Hospital
View the official record on ClinicalTrials.gov →What this trial is about
The purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age ≥ 18 years old;
- Early-stage NSCLC patients underwent radical surgical resection;
- Sufficient tumor tissue and blood sample for study use;
- Available clinical-pathologic data, imaging data and follow-up date;
- Written informed consent.
Exclusion criteria
- History of other malignant tumors;
- Evidence of distant metastasis before surgery;
- Insufficient tumor tissue or blood sample for study use;
- Clinical-pathologic data, imaging data or follow-up date is not available;
- Other judgments by the Investigator that the patient should not participate in the study.
Where it is running
1 location listed.
- Peking University People's Hospital - Beijing, China